Allergan Biocell Textured Breast Lawsuit (MDL-2921) — Eligibility, Settlement Updates, and How to File

Allergan biocell textured breast lawsuit cases continue to grow across the United States. This federal litigation targets Allergan, a major pharmaceutical company now owned by AbbVie. Plaintiffs allege that Allergan’s BIOCELL textured breast implants caused a rare cancer called BIA-ALCL. The FDA requested a worldwide recall of these implants in July 2019. As a result, thousands of women have filed claims seeking compensation for serious health consequences. The litigation is now one of the largest active medical device MDLs in the federal court system.

Case Timeline

Last checked: September 03, 2026

Advertisement

  • August 03, 2026 (Settlement): AbbVie’s Form 10-Q filed August 3, 2026 publicly disclosed that in June 2026 it reached an agreement to resolve substantially all U.S.-based BIA-ALCL lawsuits over Allergan Biocell implants, which are to be dismissed with prejudice. (Court Record)
  • August 03, 2026 (Case Status): The same August 3, 2026 AbbVie filing reports roughly 1,300 non-ALCL Biocell cases still coordinated pretrial in MDL-2921 (D.N.J.), plus about 475 in U.S. state courts and 1,080 abroad. (Court Record)
  • July 10, 2026 (Bellwether Date): First bellwether (surgical explant) trial is set for October 19, 2026, a one-plaintiff trial with the plaintiff to be selected by the Court by June 30, 2026 from six work-up cases. (Court Record)
  • July 10, 2026 (Bellwether Date): A second surgical explant bellwether trial is scheduled for a date after October 19, 2026, also drawn from the six work-up cases. (Court Record)
  • July 10, 2026 (Ruling): CMO deadlines set case-specific fact discovery completion by February 6, 2026, with plaintiffs’ opening expert reports due February 12, defense responsive reports March 23, and plaintiffs’ rebuttal reports April 27, 2026. (Court Record)
  • July 10, 2026 (Case Status): As of June 2026 the MDL has roughly 1,261–1,488 pending actions before Judge Brian R. Martinotti in the District of New Jersey, up about 18% from January 2025. (Court Record)
  • July 10, 2026 (Settlement): No global settlement or public settlement benchmarks have been announced; resolution remains individualized pending the first bellwether verdict. (Court Record)
  • July 01, 2026 (Case Status): JPML’s July 1, 2026 pending-actions report lists 1,261 actions pending in MDL-2921 before Judge Brian R. Martinotti in the District of New Jersey. (Court Record)
  • June 26, 2026 (Bellwether Date): First bellwether trial (surgical explant case) is set for October 19, 2026, with the single plaintiff to be chosen by the Court from six work-up cases by June 30, 2026. (Court Record)
  • June 26, 2026 (Ruling): Case Management Order No. 37 (filed October 14, 2025) sets the trial schedule and pretrial deadlines, including completion of case-specific fact discovery by February 6, 2026 and expert/motion deadlines running February–September 2026. (Court Record)
  • What Is the Allergan Biocell Textured Breast Lawsuit About?

    MDL Detail Current Data
    MDL Number MDL-2921
    Pending Cases 1,496
    Presiding Judge Brian R. Martinotti
    Federal District NJ
    Data Source U.S. Judicial Panel on Multidistrict Litigation
    Last Updated August 03, 2026

    The allergan biocell textured breast lawsuit centers on a specific product line. Allergan manufactured BIOCELL textured breast implants and tissue expanders for both cosmetic and reconstructive surgery. These implants used a unique “salt-loss” texturing process. This process created an aggressive, macro-textured surface unlike smoother alternatives. Researchers linked this texture to breast implant-associated anaplastic large cell lymphoma, known as BIA-ALCL.

    BIA-ALCL is a rare but serious cancer of the immune system. It typically develops in the scar tissue surrounding the implant. Symptoms include persistent swelling, pain, lumps, and breast asymmetry. In some cases, BIA-ALCL can spread to lymph nodes and become life-threatening. The FDA reported 573 unique BIA-ALCL cases worldwide at the time of the recall. Of those cases, 481 — roughly 84 percent — were linked to Allergan textured implants specifically.

    However, BIA-ALCL is not the only injury alleged in the allergan biocell textured breast lawsuit. Many plaintiffs also claim they suffered capsular contracture, chronic pain, and autoimmune-like symptoms. Others required costly explant surgery to remove the recalled devices. Allergan faces allegations of failing to warn patients and doctors about known risks. Plaintiffs argue the company prioritized profits over patient safety for years.

    MDL Case Status and Key Facts

    Detail Information
    MDL Number 2921
    Full Case Name In Re: Allergan Biocell Textured Breast Implant Products Liability Litigation
    Presiding Judge Chief Judge Renee M. Bumb
    Federal District U.S. District Court, District of New Jersey
    Approximate Pending Actions 1,485 (as of April 2026)
    First Bellwether Trial Scheduled for October 19, 2026
    Qualified Settlement Fund Established via CMO 38 (December 2025)

    The Judicial Panel on Multidistrict Litigation centralized this case in December 2019. Chief Judge Renee M. Bumb oversees all pretrial proceedings in the District of New Jersey. As of April 2026, approximately 1,485 individual actions are pending. The allergan biocell textured breast lawsuit docket has grown steadily since consolidation.

    In October 2025, the court issued Case Management Order No. 37. This order established a refined bellwether trial schedule for 2026. The first surgical explant trial is set for October 19, 2026. The court will select one plaintiff from six cases being prepared. For example, this bellwether case will test how juries respond to the evidence. Its outcome could shape future settlement negotiations significantly.

    Who Qualifies for the Allergan Biocell Textured Breast Lawsuit?

    Eligibility for the allergan biocell textured breast lawsuit depends on several factors. You may qualify if you received Allergan BIOCELL textured breast implants or tissue expanders. This includes implants used for cosmetic augmentation or post-mastectomy reconstruction. The recalled products were sold and implanted over many years before the 2019 recall.

    Typically, the strongest claims involve a BIA-ALCL diagnosis. However, women who underwent explant surgery due to the recall may also have valid claims. In most cases, plaintiffs need medical records confirming their implant type. Product identification cards, surgical records, or insurance documentation can establish this. Evidence of physical injury, emotional distress, or financial loss strengthens a claim further.

    You might be eligible to file even without a cancer diagnosis. The allergan biocell textured breast lawsuit includes claims for monitoring costs and preventive explant surgery. Women who experienced capsular contracture, chronic inflammation, or other complications may also qualify. Consulting a licensed attorney is the best way to evaluate your specific situation and understand your legal options.

    How to File an Allergan Biocell Textured Breast Lawsuit Claim

    Filing an allergan biocell textured breast lawsuit claim typically begins with a legal consultation. Most mass tort attorneys offer free case evaluations. During this review, a lawyer will assess your medical history and implant records. They will determine whether your injuries fall within the scope of MDL-2921. Attorneys in this litigation generally work on a contingency fee basis.

    After retaining counsel, your attorney will file a complaint in the MDL. You will then need to complete a Plaintiff Fact Sheet. This standardized document collects key information about your implants and medical history. It includes details about when you received implants, your symptoms, and your treatment. Timely completion of this form is critical to keeping your case active.

    The statute of limitations varies by state. In most cases, the clock starts when you discovered or should have discovered the injury. However, the 2019 FDA recall may affect how courts calculate this deadline. As a result, filing sooner rather than later is advisable. An experienced allergan biocell textured breast lawsuit attorney can advise you on your state’s specific deadline. Do not delay in seeking legal guidance.

    📨 Get Free Mass Tort Guides Alerts

    Free · No spam · Unsubscribe anytime

    Settlement Updates and What to Expect

    As of May 2026, no global settlement has been announced in the allergan biocell textured breast lawsuit. The court established a Qualified Settlement Fund through CMO 38 in December 2025. This administrative step typically signals that settlement discussions are underway. However, no court-approved settlement program currently exists for all plaintiffs.

    The upcoming October 2026 bellwether trial is a pivotal moment. Bellwether trials test representative cases before a jury. Their outcomes often influence settlement values across the entire MDL. If the plaintiff prevails, Allergan may face increased pressure to negotiate. If the defense wins, it could slow settlement momentum. Either way, the verdict will provide valuable data points for both sides.

    Settlement amounts in medical device litigation vary widely based on individual circumstances. Factors that typically affect compensation include the severity of injury, type of diagnosis, number of surgeries required, and lost income. BIA-ALCL cases generally carry higher potential value than monitoring-only claims. The allergan biocell textured breast lawsuit timeline remains uncertain, but progress toward resolution is evident. Plaintiffs should prepare for a process that may extend into 2027 or beyond.

    State-by-State Considerations

    While the allergan biocell textured breast lawsuit is centralized in federal court in New Jersey, state laws still matter. Each plaintiff’s home state determines the applicable statute of limitations and damages caps. For example, states like New Jersey, California, Texas, Florida, and New York have significant plaintiff populations in this MDL. New Jersey also maintains a separate multicounty litigation track in Bergen County for state court claims.

    State tort reform laws can limit recoverable damages. Some states cap non-economic damages such as pain and suffering. Others have modified joint and several liability rules. These differences can meaningfully affect the value of individual claims. Plaintiffs should consult an allergan biocell textured breast lawsuit attorney licensed in their home state. Understanding your state’s legal landscape is essential to setting realistic expectations. You can review state-by-state tort reform guides for more details on how local laws may apply.

    Frequently Asked Questions

    Do I need to remove my Allergan BIOCELL implants to file a lawsuit?

    No, you do not necessarily need to have your implants removed before filing. The allergan biocell textured breast lawsuit includes claims from women with implants still in place. However, the FDA recommends monitoring for symptoms. Consult both your doctor and a licensed attorney to determine the best course of action for your health and your legal claim.

    How long will the Allergan BIOCELL breast implant MDL take to resolve?

    The timeline remains uncertain as of mid-2026. The first bellwether trial is scheduled for October 2026. In most cases, MDL litigation takes several years to reach a resolution. Settlement negotiations may accelerate after bellwether results are known. Plaintiffs should be prepared for a multi-year process.

    What is BIA-ALCL and how is it connected to Allergan implants?

    BIA-ALCL stands for breast implant-associated anaplastic large cell lymphoma. It is a rare cancer of the immune system found near textured breast implants. The FDA determined that Allergan BIOCELL implants carry roughly six times the BIA-ALCL risk compared to other textured implants. Early detection and treatment are critical. If you experience unusual swelling or pain around your implants, seek medical attention promptly.

    Check If You May Qualify

    Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.

    Official Sources & Resources

    For verified mass tort and MDL information:

    Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.

    Related Guides

    Going through divorce too? Compare state laws at Divorce Help Guide. Affected by a recalled drug as a Medicare patient? See Medicare Cover Guide. Just diagnosed with a serious illness? Compare life insurance at Life Insure Guide. PFAS in your water? Check homeowners coverage at Home Insure Guide.